65,437 trials
Influenza Immunization · Healthy Volunteers
Primary: Number of Participants Aged 6 Months to <9 Years Who Provided Serum Samples for Analysis: Groups 1 and 2 — 28; 31; 20; 31 Participants
Insomnia Chronic · Cannabis Use
Primary: Change From Baseline Insomnia Severity Index Score at Study Completion — 11.2; 12.6; 6.0; 8.8 units on a scale — p=0.0041
Exocrine Pancreatic Insufficiency (EPI) · Cystic Fibrosis (CF)
Primary: Safety of MS1819 by Number of Subjects Reporting 1 or More Adverse Events — 1; 0; 2; 0 Participants
Anemia Associated With End Stage Renal Disease (ESRD)
Primary: Percentage of Participants With Mean Hb Value ≥10 g/dL — 84.7 percentage of participants
Triple Negative Breast Cancer
Primary: Efficacy of Olaparib Alone as Assessed by PFS (Progression-free Survival) Reported as Events Per Month — 0.18 events/month — p=0.0023
Internal Hemorrhoids
Primary: Reduction in Swelling — 2.3; 2.0 scores on a scale — p=0.8918
Multiple Myeloma
Primary: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria — 70.4 percentage…
Peripheral T-cell Lymphoma NOS · Mycosis Fungoides · Sezary Syndrome
Primary: Maximum Tolerated Dose (MTD) of Interleukin 15 — NA; NA mcg/kg
SARS-CoV-2 · COVID-19
Primary: Composite of the Maximum Sequential Organ Failure Assessment (SOFA) Score and Death Within 30 Days — 0; 1 score on a scale
Partly Edentulous Maxilla
Primary: Mean Change of Bone Level — -0.34; -0.15; -0.24; -0.12 mm
Nicotine Dependence · Smoking Cessation
Primary: Self-reported Nicotine Consumption — 27.55; 26.83; 30.00 cigarettes/day
Congenital Heart Disease
Primary: Change From Baseline in Peak Oxygen Uptake/Consumption (VO2) Up to Week 16 — -0.67; -0.16 Milliliter/kilogram/minute (mL/kg/min) — p== 0.1930
Multiple Myeloma
Primary: Number of Participants For Whom 2.0 x 10e6 CD34+ HSC Cells/kg Could be Collected in 1 or 2 Apheresis Harvests — 22 Participants
Opioid-use Disorder · Opioid Dependence · Treatment Adherence
Primary: Treatment Adherence — 16; 13 Participants
Leukemia, Myeloid · Isocitrate Dehydrogenase
Primary: Overall Survival (OS) — 6.5; 6.2 Months — p=0.2288